Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$2.8M
Filings
68
Firms Hired
4
Active Period
2018–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Joe Fiandra Access to Home Infusion Act of 2025
2026 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Implementation of HR 4993 the Joe Fiandra Access to Home Infusion Act, including issues in CMS-1828-P; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines
Client expense: — · Firm income: $60,000
Matched citations: HR 4993
Joe Fiandra Access to Home Infusion Act of 2025
2026 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
Implementation of HR 4993 the Joe Fiandra Access to Home Infusion Act, including issues in CMS-1828-P; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines
Client expense: — · Firm income: $60,000
Matched citations: HR 4993
Mikaela Naylon Give Kids a Chance Act
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
S 932/HR 1262 Mikaela Naylon Give Kids a Chance Act of 2025; Preserving US competitiveness and patient access to lifesaving medicines; HR 7148 the Consolidated Appropriations Act of 2026
Client expense: — · Firm income: $50,000
Matched citations: HR 1262
Joe Fiandra Access to Home Infusion Act of 2025
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4993 the Joe Fiandra Access to Home Infusion Act; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines; HR 7148 the Consolidated Appropriations Act of 2026
Client expense: — · Firm income: $50,000
Matched citations: HR 4993
Consolidated Appropriations Act, 2026
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
S 932/HR 1262 Mikaela Naylon Give Kids a Chance Act of 2025; Preserving US competitiveness and patient access to lifesaving medicines; HR 7148 the Consolidated Appropriations Act of 2026
Client expense: — · Firm income: $50,000
Matched citations: HR 7148
Consolidated Appropriations Act, 2026
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4993 the Joe Fiandra Access to Home Infusion Act; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines; HR 7148 the Consolidated Appropriations Act of 2026
Client expense: — · Firm income: $50,000
Matched citations: HR 7148
Give Kids a Chance Act of 2025
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
S 932/HR 1262 Mikaela Naylon Give Kids a Chance Act of 2025; Preserving US competitiveness and patient access to lifesaving medicines; HR 7148 the Consolidated Appropriations Act of 2026
Client expense: — · Firm income: $50,000
Matched citations: S 932
Mikaela Naylon Give Kids a Chance Act
2025 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
S 932/HR 1262 Mikaela Naylon Give Kids a Chance Act of 2025; Preserving US competitiveness and patient access to lifesaving medicines
Client expense: — · Firm income: $50,000
Matched citations: HR 1262
Joe Fiandra Access to Home Infusion Act of 2025
2025 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4993 the Joe Fiandra Access to Home Infusion Act; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines
Client expense: — · Firm income: $50,000
Matched citations: HR 4993
Give Kids a Chance Act of 2025
2025 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
S 932/HR 1262 Mikaela Naylon Give Kids a Chance Act of 2025; Preserving US competitiveness and patient access to lifesaving medicines
Client expense: — · Firm income: $50,000
Matched citations: S 932
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: HR 1
Mikaela Naylon Give Kids a Chance Act
2025 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: HR 1262
Joe Fiandra Access to Home Infusion Act of 2025
2025 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 4993 the Joe Fiandra Access to Home Infusion Act
Client expense: — · Firm income: $50,000
Matched citations: HR 4993
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: HR 946
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: S 1862
Give Kids a Chance Act of 2025
2025 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: S 932
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: HR 1
Mikaela Naylon Give Kids a Chance Act
2025 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: HR 1262
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: HR 946
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: S 1862
Give Kids a Chance Act of 2025
2025 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932/HR 1262 Give Kids a Chance Act of 2025; S 1862/HR 946 Orphan Cures Act; Importance of patient access to treatments in HR 1 (Public Law 119-21)
Client expense: — · Firm income: $50,000
Matched citations: S 932
Give Kids a Chance Act of 2025
2025 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
Priority Review Voucher extension; S 932 Give Kids a Chance Act of 2025
Client expense: — · Firm income: $50,000
Matched citations: S 932
Joe Fiandra Access to Home Infusion Act of 2023
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 5397
Seniors’ Access to Critical Medications Act of 2024
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5397 the Joe Fiandra Access to Home Infusion Act, HR 5526 Seniors' Access to Critical Medications Act; HR 8816 American Medical Innovation and Investment Act; Issues related to patient access to rare disease therapies
Client expense: — · Firm income: $50,000
Matched citations: HR 5526
Creating Hope Reauthorization Act of 2024
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Extension of Priority Review Vouchers in S 4583; HR 7384 the Creating Hope Reauthorization Act, FDA reforms to improve rare disease patient perspective input and flexibilities
Client expense: — · Firm income: $50,000
Matched citations: HR 7384
Source: Senate LDA